Skip to main content

Sign in Register

Market DashboardMarkets, breadth and flows IndicesNSE & BSE benchmarks SectorsToday's rotation HeatmapSize = cap, colour = move BreadthAdvancers vs decliners FII/DIIInstitutional flows ValuationIs the market expensive?

SCREENER STOCKS FILINGS

Intelligence

Situations Conviction Broker Reports Earnings Deliveries Deals Corp. Actions

Discovery

Themes IPO Funds Community

PORTFOLIO MY AI

after·markets

Track what you own. Screen what you don't. India's market intelligence: screening, conviction scoring, and filing analysis, alive in real time.

Data: NSE & BSE

contact@aftermarkets.in

Markets

Market Dashboard
Screener
All Stocks
Heatmap
FII / DII

Research

Research hub
Filings
Conviction
Earnings
Broker Reports
Deliveries
Valuation
Deals
Themes
IPO Tracker
Funds & PMS

You

Portfolio
Trade Journal
Alerts
Watchlist
Get started

Company

About
Pricing
Learn
Developer / MCP
Terms
Privacy
Disclaimer

Operated by Chainlytics Advisory Services LLP.

© 2026 aftermarkets.in · Mumbai, IndiaInvestment in securities market are subject to market risks. Read all related documents carefully before investing.

Jubilant Pharmova Limited

NSE: JUBLPHARMA · Healthcare · Pharmaceuticals · Market cap ₹15,356 Cr

₹964.10▾−18.85 (−1.92%)

· Prev close ₹982.95 · Volume 54.76 K · 52W ₹786–1,162

13 Nov Sep-quarter results

Jubilant Pharmova ₹964.10 ▾−1.92%Results 13 Nov

⇧⌘K

Company research

Overview
Profitability2
Growth5
Valuation5
Financial health5
Ownership5
Price momentum6
Filings & calls9
Company8

Every dataset is a tab inside its group. Search finds any of them, including old names such as “concall”.
Find a dataset: Ctrl/⌘ Shift K
Find another stock: Ctrl/⌘ K

Jubilant Pharmova › Profitability

Profitability

Key figures Returns & margins

Loading selected research…

← PreviousOverview Next →Profitability · Returns & margins

Return on capital: 8.5%; 6th of 6 · latest reported
Return on equity: 6.0%; 6th of 6 · latest reported
: 13.3%; last 4 quarters · FY26 16.0%
: 2.9%; last 4 quarters · FY26 4.8%
Business score: 43/100; 4 of 4 factors scored · See the factors

Return on capital (ROCE)6 listed peers

Profit before interest and tax per ₹100 of capital employed.

1CORONA Remedies27.6%
2Pfizer22.9%
3AstraZeneca Pharma India19.1%
4Marksans Pharma18.2%
5Natco Pharma14.7%
6Jubilant Pharmova8.5%

Median of the other 5: 19.1%

Return on equity (ROE)6 listed peers

Net profit per ₹100 of shareholders' equity.

1CORONA Remedies27.4%
2Marksans Pharma25.6%
3Pfizer17.2%
4Natco Pharma16.9%
5AstraZeneca Pharma India15.7%
6Jubilant Pharmova6.0%

Median of the other 5: 17.2%

Operating margin, last 8 quartersoperating profit ÷ revenue

15.8%18.5%15.9%17.9%14.6%15.9%12.0%10.8%

Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26

Last 4 quarters 13.3%